drugset
drugset / Trial / NCT07209332

Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy

NCT07209332 ↗

Phase 2 Enrolling by invitation 175 enrolled Wave Life Sciences USA, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 2 open-label extension (OLE) study to evaluate the long-term safety, tolerability, efficacy, pharmacokinetics, and the pharmacodynamics (PD) through potential exploratory biomarker(s) of intravenous (IV) WVE-N531 in patients with DMD who participated in another study of WVE-N531. All patients will have rolled over from a previous study of WVE-N531.

Timeline

Start
2025-12-28
Primary completion
2029-03
Completion
2029-03

Drugs

EvaluationDrugModalityDoseRoute
Subject WVE-N531 Antisense oligonucleotide 10 mg/kg Intravenous

Indications

Duchenne muscular dystrophy